FDA grants Priority Review to subcutaneous amivantamab for advanced head and neck cancer treatment
The FDA has granted Priority Review to Johnson & Johnson's subcutaneous amivantamab for treating adults with recurrent or metastatic head and neck squamous cell carcinoma after progression on chemotherapy and immunotherapy. This drug uniquely targets...
